

• **Name: Youngil Koh**

• **Affiliation/Current Position: Seoul National University Hospital, Associate Professor**

• **Country: Korea**

• **ICKSH2022 Presentation Title:**

• **Educational Background:**

**PhD, Seoul National University, Molecular Oncology**

**MD, Seoul National University**

• **Professional Experiences:**

Associate Professor, Seoul National University, Hematology-Oncology 2019-

Assistant Professor, Seoul National University, Hematology-Oncology 2014-

• **Professional Organizations**

Chairman of Planning, Korea Genome Organization

Steward, Education Committee, The Korean Society of Hematology

• **Main Scientific Publications:**

1. Koh Y, Lee HE, Im SA, et al. VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. Diagnostic molecular pathology : the American journal of surgical pathology, part B 2011;20:143-7.

2. Kim I, Koh Y, Yoon SS, et al. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. American journal of hematology 2013;88:10-5.

3. Park S, Koh Y, Jung SH, Chung YJ. Application of array comparative genomic hybridization in chronic myeloid leukemia. Methods in molecular biology 2013;973:55-68.

4. Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24:1026-31.

5. Koh Y, Kim I, Shin DY, et al. Polymorphisms in genes that regulate cyclosporine metabolism affect cyclosporine blood levels and clinical outcomes in patients who receive allogeneic

hematopoietic stem cell transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation* 2012;18:37-43.

6. Koh Y, Lee HE, Oh DY, et al. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. *Japanese journal of clinical oncology* 2012;42:1020-7.

7. Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2011;6:905-12.

8. Koh Y, Jang B, Jeon YK, et al. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. *Japanese journal of clinical oncology* 2011;41:548-54.

9. Koh Y, Kim DY, Park SH, et al. GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization. *Cancer genetics and cytogenetics* 2010;203:215-21.

10. Koh Y, Kim I, Bae JY, et al. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8. *Japanese journal of clinical oncology* 2010;40:1037-45.

11. Koh Y, Lee HR, Song EY, et al. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA). *Leukemia research* 2010;34:1344-50.

12. Koh Y, Kim I, Yoon SS, et al. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. *Annals of hematology* 2010;89:725-31.

13. Koh Y, Jang B, Han SW, et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2010;5:320-5.

14. Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. *Annals of hematology* 2010;89:201-6.

15. Koh Y, Kim TM, Jeon YK, et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2009;20:1414-9.

16. Koh Y, Park J, Ahn KS, et al. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway. *Annals of hematology* 2009;88:1089-97.

17. Koh Y, Park J, Bae EK, et al. Non-A type nucleophosmin 1 gene mutation predicts poor clinical

- outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. *International journal of hematology* 2009;90:1-5.
18. Koh Y, Jung WJ, Ahn KS, Yoon SS. Establishment of cell lines from both myeloma bone marrow and plasmacytoma: SNU\_MM1393\_BM and SNU\_MM1393\_SC from a single patient. *BioMed research international* 2014;2014:510408.
19. Koh Y, Lee SY, Kim I, et al. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. *Cancer chemotherapy and pharmacology* 2014;74:653-7.
20. Park H, Youk J, Kim I, et al. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia. *Annals of hematology* 2016;95:1777-86.
21. Youk J, Koh Y, Kim JW, et al. A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data. *Blood research* 2016;51:17-22.
23. Koh Y, Park I, Sun CH, et al. Detection of a Distinctive Genomic Signature in Rhabdoid Glioblastoma, A Rare Disease Entity Identified by Whole Exome Sequencing and Whole Transcriptome Sequencing. *Translational oncology* 2015;8:279-87.
24. Lee KW, Koh Y, Kim SB, et al. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. *The oncologist* 2015;20:1119-20.
25. Byun JM, Koh Y, Shin DY, et al. BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. *Haematologica*. May 2017;102(5):e187-e190.
26. Park H, Youk J, Shin DY, et al. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. *BMC Cancer*. 2019;19(1):358.
27. Song H, Lim Y, Im H, et al. Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus). *Sci Rep*. 2019;9(1):3465.
28. Shin J, Ko YH, Oh SY, et al. Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. *Cancer Res Treat*. 2019.
29. Ock CY, Seo H, Kim DY, et al. Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia. *Leuk Lymphoma*. 2019;60(7):1775-1781.
30. Kim SA, Lee J, Moon JH, et al. Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors. *Ann Hematol*. 2019;98(2):501-510.
31. Koh Y, Lee JM, Woo GU, et al. FDG PET for Evaluation of Bone Marrow Status in T-Cell Lymphoma. *Clin Nucl Med*. 2019;44(1):4-10.
32. Choi M, Jeon YK, Sun CH, et al. RTK-RAS pathway mutation is enriched in myeloid sarcoma. *Blood Cancer J*. 2018;8(5):43.

33. Min JW, Koh Y, Kim DY, et al. Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients. *Mol Cells*. 2018;41(5):465-475.
35. Shin J, Kim D, Kim HL et al. Oncogenic effects of germline variants in lysosomal storage disease genes. *Genet Med* 2019.
36. Suh KJ, Shin DY, Kim I et al. Comparison of quality of life and health behaviors in survivors of acute leukemia and the general population. *Ann Hematol* 2019; 98: 2357-2366.
37. Kim D, Koh Y, Yoon SS. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition. *Anticancer Res*. 2020;40(3):1395-1403.
38. Yoon J, Lee S, Sun CH, et al. MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method. *Thromb Res*. 2020;193:154-159.
39. Ha JH, Lee C, Lee KS, et al. The molecular pathogenesis of Trichilemmal carcinoma. *BMC Cancer*. 2020;20(1):516.
40. Byun JM, Song S, Koh Y, Yoon SS, Kim D. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms. *Anticancer Res*. 2019;39(11):6273-6282.
41. Lee S, Song S, Yoon SS, et al. Proper Read Filtering Method to Adequately Analyze Whole-Transcriptome Sequencing and RNA Based Immune Repertoire Sequencing Data for Tumor Milieu Research. *Cancers (Basel)* 2020;12.
42. Ku J, Kim R, Kim D, et al. Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer. *Commun Biol* 2020;3:630.
43. Bolton K, Koh Y, Foote M et al. Clonal hematopoiesis is associated with risk of severe Covid-19, *Nat Comm*, 2021;Oct 13;12(1):5975